Technical Analysis for PTEO - Proteo, Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | N/A | Down | Down |
See historical PTEO trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Resistance | Bearish | -1.70% | |
Fell Below 20 DMA | Bearish | -1.70% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.70% | |
Wide Bands | Range Expansion | -1.70% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Biotechnology
Proteo, Inc. is a clinical-stage drug development company. The Company intends to develop, promote and market pharmaceuticals and other biotech products. The Company's focus is on the development of anti-inflammatory treatments for rare diseases with unmet needs. The Company is engaged in the development of pharmaceuticals based on the body's own tools and weapons to fight inflammatory diseases. The Company is focusing its research on the development of drugs based on the human protein, Elafin. The Company has obtained Orphan drug designations within the European Union for the use of Elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, as well as for the treatment of esophageal cancer. Within the United States, it has obtained Orphan drug designations for the use of Elafin for the treatment of pulmonary arterial hypertension, as well as for the prevention of inflammatory complications of transthoracic esophagectomy.
Health Pharmaceuticals Life Sciences European Union Hypertension Drug Development Rare Diseases Inflammatory Diseases Pulmonary Arterial Hypertension Pulmonary Hypertension Esophageal Cancer
Health Pharmaceuticals Life Sciences European Union Hypertension Drug Development Rare Diseases Inflammatory Diseases Pulmonary Arterial Hypertension Pulmonary Hypertension Esophageal Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Date | Title |
---|
Indicator | Value |
---|---|
52 Week High | 0.349 |
52 Week Low | 0.01 |
Average Volume | 73,406 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.0631 |
20-Day Moving Average | 0.0539 |
10-Day Moving Average | 0.0521 |
Average True Range | 0.0210 |
ADX | 55.13 |
+DI | 47.1272 |
-DI | 12.0725 |
Chandelier Exit (Long, 3 ATRs ) | 0.0799 |
Chandelier Exit (Short, 3 ATRs ) | 0.1030 |
Upper Bollinger Band | 0.0826 |
Lower Bollinger Band | 0.0252 |
Percent B (%b) | 0.37 |
BandWidth | 106.4935 |
MACD Line | -0.0029 |
MACD Signal Line | -0.0027 |
MACD Histogram | -0.0002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0537 | ||||
Resistance 3 (R3) | 0.0545 | 0.0529 | 0.0525 | ||
Resistance 2 (R2) | 0.0529 | 0.0510 | 0.0525 | 0.0520 | |
Resistance 1 (R1) | 0.0495 | 0.0498 | 0.0487 | 0.0487 | 0.0516 |
Pivot Point | 0.0479 | 0.0479 | 0.0475 | 0.0475 | 0.0479 |
Support 1 (S1) | 0.0445 | 0.0460 | 0.0437 | 0.0437 | 0.0408 |
Support 2 (S2) | 0.0429 | 0.0448 | 0.0425 | 0.0404 | |
Support 3 (S3) | 0.0395 | 0.0429 | 0.0400 | ||
Support 4 (S4) | 0.0387 |